Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

Siemens Healthineers AG. (1/5/21). "Press Release: Siemens Healthineers Proposes Peer Schatz to Annual Shareholders' Meeting as New Supervisory Board Member". Erlangen.

Organisations Organisation Siemens Healthineers AG (Frankfurt: SHL)
  Group Siemens (Group)
  Organisation 2 PS Capital Management GmbH (Peer Schatz)
Products Product MedTech (medical technology)
  Product 2 diagnostics (medical/biological)
Persons Person Schatz, Peer M. (Resolve BioSciences 202012 Chairman + Co-Founder before Qiagen 1993–201910 CEO RESIGNED 10/19)
  Person 2 Thomas, Ralf P. (Siemens 201711 CFO)

> Extension of the Supervisory Board expertise will cover the company’s portfolio in an ideal way

> Peer Schatz is an outstanding expert in laboratory diagnostics, precision medicine and digitalization with an international background

> Proposed term of five years

The Supervisory Board of Siemens Healthineers AG is proposing a new Supervisory Board member to the shareholders for election at the Annual Shareholders' Meeting on February 12, 2021: Peer Schatz (55), long-serving CEO of QIAGEN N.V., a leading global provider of complete solutions for gaining molecular insights from biological samples. Schatz, who lived and worked in the U.S. for many years, has more than 30 years of expertise in life sciences, precision medicine and bioinformatics.

If Peer Schatz were elected, the number of Supervisory Board members of Siemens Healthineers AG would increase from currently nine to ten. The Annual Shareholders' Meeting will first have to take a decision on an amendment to the Articles of Association, which allows a higher number of members on the Supervisory Board. The election would be for a term of five years.

"With Peer Schatz, an outstanding entrepreneur and one of the most internationally renowned and recognized diagnostic experts is up for election. His many years of extensive experience will be an excellent addition to the expertise of the Supervisory Board, especially with regard to the important areas of diagnostics and digitalization. With the nomination, we also reflect the increased demands on the company by its growing internationality," explains Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board of Siemens Healthineers AG.

At the beginning of his professional career, Peer Schatz held various positions at Sandoz AG and Computerland, and was involved in creating various start-up companies in Europe and the USA. In 1993, he joined QIAGEN – at a time when the company had about 30 employees and revenue of USD 2 million. Under his leadership, QIAGEN grew into a global company with more than 5,100 employees and annual revenues of more than USD 1.5 billion. Peer Schatz is currently Managing Director of PS Capital Management GmbH as well as Chairman of the Supervisory Board of Centogene N.V. and co-founder and Chairman of the Board of Resolve Biosciences GmbH.

Peer Schatz was a founding member of the “Deutsche Corporate Governance Kommission” in Germany that developed the first corporate governance framework that is still the guiding standard in the country today. He was also co-chair of the World Economic Forum's Precision Medicine Council from 2016 to 2020. Peer Schatz is of Austrian and Swiss nationality. He studied at the University of St. Gallen in Switzerland, where he received a master's degree in 1989. In 1991, he earned a Master of Business Administration degree from the Graduate School in Business at the University of Chicago.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at


Matthias Kraemer
Karlheinz Kaske Straße 5
91052 Erlangen
tel: 0049-172-3440114

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Siemens (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top